Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCDI molecular characterization initiative. This is an ASCO Meeting Abstract from the 2025 ASCO ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML). CR after induction chemotherapy (OR, CI 95%).

AUSTIN, TX and DURHAM, NC, May 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class ...